Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
The Specialty of Cleaning up: Change Your Space and Brain- Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
- Incredible Travel Objections for Craftsmanship Darlings to Visit
- Interoceanic Train derails in southern Mexico, injuring at least 15 and halting traffic on line
- Rediscovering Imagination in Adulthood: Individual Creative Excursions
- Instructions to Plan for Your Teeth Substitution Methodology
- 5 Language Learning Applications
- The Best Web-based Courses for Ability Advancement
- Astronauts' brains change shape and position after time in space, study finds
